EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) mutations, found in 32.3% to 50.7% of NSCLC patients in Asia [3–5], are commonly treated with EGFR tyrosine kinase inhibitors (TKIs).